AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Convatec Group PLC

Board/Management Information Jul 6, 2018

4959_dirs_2018-07-06_544779c8-2808-42bb-a738-10a034aac5c5.html

Board/Management Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8501T

ConvaTec Group PLC

06 July 2018

Reading, United Kingdom (6 July 2018) -  Further to the announcement on 3 July 2018 of the appointment of Sten Scheibye as a Non-Executive Director of ConvaTec Group Plc, it is confirmed that there are no disclosures to be made pursuant to LR 9.6.13 in relation to the appointment of Sten Scheibye.

Enquiries

Media

Bobby Leach, VP Group Corporate Affairs, ConvaTec                    +44 (0)7770 842 226

Alastair Elwen, Finsbury                                                             +44 (0)207 251 3801

Analysts and Investors

John Crosse, VP Investor Relations, ConvaTec                             +44 (0)7500 141 435

Kirsty Law, Director Investor Relations, ConvaTec                         +44 (0)7470 909 582

[email protected]

ConvaTec Group Plc’s LEI code is 213800LS272L4FIDOH92

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

RDNUGUMCMUPRURQ

Talk to a Data Expert

Have a question? We'll get back to you promptly.